Anzeige
Mehr »
Login
Samstag, 05.10.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
Achtung Vervielfachung! URAN-AKTIEN starten durch …. Jetzt kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 917184 | ISIN: US2210061097 | Ticker-Symbol:
NASDAQ
04.10.24
22:00 Uhr
316,60 US-Dollar
+4,80
+1,54 %
1-Jahres-Chart
CORVEL CORPORATION Chart 1 Jahr
5-Tage-Chart
CORVEL CORPORATION 5-Tage-Chart
GlobeNewswire (Europe)
235 Leser
Artikel bewerten:
(1)

CorVel Corp.: CorVel Announces Revenues and Earnings

FORT WORTH, Texas, July 30, 2024 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter ended June 30, 2024. Revenues for the quarter were $212 million, an increase from $190 million in the June quarter of 2023. Earnings per share for the quarter were $1.25, compared to $1.14 in the same quarter of the prior year.

First Quarter Fiscal Year 2025 Highlights

  • Revenue increased 11% to $212 million, compared to first quarter of fiscal year 2024.
  • Gross profit increased 15% to $48.2 million, at 22.7% gross margin, compared to first quarter of fiscal year 2024 gross profit of $41.9 million.
  • Diluted earnings per share increased 10% to $1.25, compared to first quarter of fiscal year 2024 diluted earnings per share of $1.14.
  • Exited the quarter with $132 million of cash, cash equivalents, and no borrowings.
  • The Company repurchased $9.5 million of common stock during the quarter.

During the quarter, the Company introduced an enhanced communications platform integrated in CorVel's proprietary claims system, CareMC. This platform benefits claim staff and injured workers and yields a level of efficiency that is unique in the industry. Additionally, the platform utilizes the advanced security features embedded in the system, reducing patient security risk.

Artificial intelligence is also being used in the review of clinical bills to identify anomalies and document activities. This utilization of AI allows the users to focus on reviewing procedures and achieving optimal cost containment. The Company believes the use of AI in partnership with the CorVel team will provide improved outcomes for partners, enhanced experience for workers with injuries, and increased job satisfaction for team members.

About CorVel

CorVel Corporation applies technology including artificial intelligence, machine learning and natural language processing to enhance the managing of episodes of care and the related health care costs. We partner with employers, third-party administrators, insurance companies and government agencies in managing workers' compensation and health, auto and liability services. Our diverse suite of solutions combines our integrated technologies with a human touch. CorVel's customized services, delivered locally, are backed by a national team to support clients as well as their customers and patients.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

All statements included in this press release, other than statements or characterizations of historical fact, are forward-looking statements. These forward-looking statements are based on the Company's current expectations, estimates and projections about the Company, management's beliefs, and certain assumptions made by the Company, and events beyond the Company's control, all of which are subject to change. Such forward-looking statements include, but are not limited to, statements relating to our improved productivity resulting from automation and augmentation across enterprise business systems. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause the Company's actual results to differ materially and adversely from those expressed in any forward-looking statement, including the risk that the impact of the COVID-19 pandemic on our business, results of operations and financial condition is greater than our initial assessment. The risks and uncertainties referred to above include but are not limited to factors described in this press release and the Company's filings with the Securities and Exchange Commission, including but not limited to "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2024 and the Company's Quarterly Report on Form 10-Q for the quarters ended June 30, 2023, September 30, 2023 and December 31, 2023. The forward-looking statements in this press release speak only as of the date they are made. The Company undertakes no obligation to revise or update publicly any forward-looking statement for any reason.

CorVel Corporation
Quarterly Results - Income Statement
Quarters Ended June 30, 2024 (unaudited) and June 30, 2023 (unaudited)

Quarter Ended June 30, 2024 June 30, 2023
Revenues $211,722,000 $190,253,000
Cost of revenues 163,567,000 148,375,000
Gross profit 48,155,000 41,878,000
General and administrative 20,120,000 16,450,000
Income from operations 28,035,000 25,428,000
Income tax provision 6,458,000 5,623,000
Net income $21,577,000 $19,805,000
Earnings Per Share:
Basic $1.26 $1.16
Diluted $1.25 $1.14
Weighted Shares
Basic 17,122,000 17,144,000
Diluted 17,313,000 17,385,000
CorVel Corporation
Quarterly Results - Condensed Balance Sheet
June 30, 2024 (unaudited) and March 31, 2024

June 30, 2024 March 31, 2024
Cash $131,908,000 $105,563,000
Customer deposits 94,022,000 88,142,000
Accounts receivable, net 97,749,000 97,108,000
Prepaid taxes and expenses 9,579,000 11,418,000
Property, net 86,865,000 85,892,000
Goodwill and other assets 42,808,000 42,498,000
Right-of-use asset, net 23,241,000 24,058,000
Total $486,172,000 $454,679,000
Accounts and taxes payable $18,681,000 $16,631,000
Accrued liabilities 181,904,000 167,868,000
Long-term lease liabilities 21,714,000 22,533,000
Paid-in capital 237,807,000 233,632,000
Treasury stock (803,431,000) (793,905,000)
Retained earnings 829,497,000 807,920,000
Total $486,172,000 $454,679,000


Contact: Melissa Storan
Phone: 949-851-1473
www.corvel.com


© 2024 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.